Chelsea is a Patent Scientist with Michael Best. Her background encompasses the areas of biochemistry, synthetic chemistry, drug development, organic chemistry, molecular biology, and pharmacology. She brings more than eight years of research experience to her role assisting clients with patent preparation and prosecution for life sciences innovations.
Chelsea earned a Ph.D. in Organic Chemistry from Saint Louis University where her work involved the synthesis and biological evaluation of novel compounds targeting G protein-coupled receptors (GPCRs). Chelsea’s graduate work resulted in her being listed as a co-inventor on U.S. Patent No. 6,247,894 entitled “Compounds and methods targeting GPER in calcium disorders.”
During Chelsea’s graduate studies, she consulted for the Biotechnology and Life Science Advising (BALSA) Group. Chelsea completed engagements for technology transfer offices, biotechnology start-ups, and a life science venture group. For these engagements, Chelsea performed comprehensive technology assessments and market analyses to generate strategic recommendations related to patenting, commercialization, and investment.
After finishing her Ph.D., Chelsea expanded her scientific expertise by completing post-doctoral training at the University of North Carolina-Chapel Hill. Chelsea’s post-doctoral research group specialized in chemical screening platforms, advanced GPCR signaling, pharmacology, biased signaling, structural biology, and psychedelics. As a post-doc, Chelsea collaborated and published with a Nobel Laureate.
Chelsea later completed Michael Best’s EDGE internship program before joining the firm in her present role.